
Nureca Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹70(17.50%)
Premium (ELP)
Nureca Limited's completed its IPO journey with a successful listing on NSE, BSE on Feb 25, 2021. The public offering mobilized 25,00,175 Shares in total capital, comprising TBD in fresh equity.
The offering was conducted within the price band of ₹396 to ₹400, with minimum application lots of 35 shares. Investor participation during the Feb 15, 2021 to Feb 17, 2021 subscription window determined the final allocation pattern.
The basis of allotment was announced on Feb 23, 2021, finalizing share distribution to successful applicants. The listing represents a significant corporate development, providing the company with enhanced visibility and access to public capital markets.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2016, Nureca Limited is a healthcare and wellness products distributor focused on providing high-quality and innovative tools for monitoring chronic diseases and improving lifestyle. The company offers a diversified portfolio including chronic care devices, orthopedic products, mother and child care products, nutrition supplements, and lifestyle products. It is the first digital company in India to sell such products through its website, drtust.in, as well as via e-commerce partners, retailers, and distributors.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Diversified Portfolio: Offers a wide range of healthcare and wellness products.
- Experienced Leadership: Promoter supported by a skilled management team.
- Strong Online Presence: Robust online distribution network.
- Premium Quality: Focus on high-quality healthcare and wellness offerings.
NA
- Saurabh Goyal
Nureca Limited
Link Intime India Private Limited
